Deferred Revenue
Alnylam Pharmaceuticals Deferred Revenue decreased by 33.7% to $3.21M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 88.6%, from $28.16M to $3.21M. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows a downward trend with a -48.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong sales of subscription-based services or bundled offerings, providing a predictable pipeline for future revenue recognition.
Detailed definition
Represents cash payments received from customers in advance of the company fulfilling its performance obligations, speci...
Peer comparison
High-growth software and services companies typically maintain larger deferred revenue balances relative to pure hardware manufacturers.
deferred_revenue_currentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $98.14M | $115.04M | $149.48M | $131.84M | $114.29M | $144.21M | $42.11M | $35.79M | $54.64M | $77.14M | $102.75M | $76.85M | $69.01M | $71.03M | $55.48M | $28.16M | $15.08M | $2.54M | $4.85M | $3.21M |
| QoQ Change | — | +17.2% | +29.9% | -11.8% | -13.3% | +26.2% | -70.8% | -15.0% | +52.6% | +41.2% | +33.2% | -25.2% | -10.2% | +2.9% | -21.9% | -49.2% | -46.4% | -83.1% | +90.7% | -33.7% |
| YoY Change | — | — | — | — | +16.5% | +25.4% | -71.8% | -72.9% | -52.2% | -46.5% | +144.0% | +114.7% | +26.3% | -7.9% | -46.0% | -63.4% | -78.1% | -96.4% | -91.3% | -88.6% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 |
|---|---|---|
| Roche Development Services Obligation | $545.00M | $545.00M |
| Roche License Obligation | $375.00M | $375.00M |
| Roche Technology Transfer Obligation | $2.00M | $2.00M |
| Total | $69.01M | $71.03M |
C5 Co-Co Obligation, Roche Development Services Obligation, Roche License Obligation, Roche Technology Transfer Obligation were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported deferred revenue of $3.21M in Q1 2026.
- How has Alnylam Pharmaceuticals's deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's deferred revenue decreased by 88.6% year-over-year, from $28.16M to $3.21M.
- What is the long-term trend for Alnylam Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's deferred revenue has grown at a -48.0% compound annual growth rate (CAGR), from $127.21M to $4.85M.
- What does deferred revenue mean?
- Money collected from customers for products or services that haven't been delivered yet but will be within a year.